相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Stepping forward in antibody-drug conjugate development
Yiming Jin et al.
PHARMACOLOGY & THERAPEUTICS (2022)
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies
Zishuo I. Hu et al.
CANCER (2021)
Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma An International Multi-Institutional Analysis
Jefree J. Schulte et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2021)
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach
Andrew G. Nicholson et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.
Amita Patnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genomics and Functional Genomics of Malignant Pleural Mesothelioma
Ece Cakiroglu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
Puey-Ling Chia et al.
PHARMACEUTICALS (2020)
Antibody-Drug Conjugates: The Last Decade
Nicolas Joubert et al.
PHARMACEUTICALS (2020)
Evaluation of PNU-159682 antibody drug conjugates (ADCs)
Dane Holte et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
Roberta Affatato et al.
CANCERS (2020)
Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone degradation and lung metastasis
Signe Z. Ingvarsen et al.
SCIENTIFIC REPORTS (2020)
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors
Jeffrey Clarke et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
Aliya Noor Husain et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Novel therapies for malignant pleural mesothelioma
Arnaud Scherpereel et al.
LANCET ONCOLOGY (2018)
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study
Lauren E. Rosen et al.
MODERN PATHOLOGY (2018)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Jutija Hmeljaki et al.
CANCER DISCOVERY (2018)
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2017)
The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers
Christoffer Fagernaes Nielsen et al.
ONCOTARGET (2017)
Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180
Lars H. Engelholm et al.
JOURNAL OF PATHOLOGY (2016)
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification
Francoise Galateau-Salle et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Colin D. Weekes et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The collagen receptor uPARAP/Endo180 in tissue degradation and cancer
Maria C. Melander et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer
Jan Nyrop Jakobsen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
Suzie J. Scales et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival
Zarah Glad Zimling et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
The Non-phagocytic Route of Collagen Uptake A DISTINCT DEGRADATION PATHWAY
Daniel H. Madsen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The collagen receptor uPARAP/Endo180
Lars H. Engelholm et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Antibody-mediated Targeting of the Urokinase-type Plasminogen Activator Proteolytic Function Neutralizes Fibrinolysis in Vivo
Ida K. Lund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Extracellular Collagenases and the Endocytic receptor, urokinase plasminogen activator receptor-associated Protein/Endo180, cooperate in fibroblast-mediated collagen degradation
Daniel H. Madsen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Increased expression of the collagen internalization receptor uPARAP/Endo180 in the stroma of head and neck cancer
Jay Sulek et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2007)
uPARAP/Endo 180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion
LH Engelholm et al.
JOURNAL OF CELL BIOLOGY (2003)
Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells
BS Nielsen et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
